Cargando…

The Role of TCF7L2 in Type 2 Diabetes

TCF7L2 is the most potent locus for type 2 diabetes (T2D) risk and the first locus to have been robustly reported by genomic linkage studies. TCF7L2 is a transcription factor that forms a basic part of the Wnt signaling pathway. This gene has highly conserved sequence regions that correspond to func...

Descripción completa

Detalles Bibliográficos
Autores principales: del Bosque-Plata, Laura, Martínez-Martínez, Eduardo, Espinoza-Camacho, Miguel Ángel, Gragnoli, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275893/
https://www.ncbi.nlm.nih.gov/pubmed/34016596
http://dx.doi.org/10.2337/db20-0573
_version_ 1783721802494640128
author del Bosque-Plata, Laura
Martínez-Martínez, Eduardo
Espinoza-Camacho, Miguel Ángel
Gragnoli, Claudia
author_facet del Bosque-Plata, Laura
Martínez-Martínez, Eduardo
Espinoza-Camacho, Miguel Ángel
Gragnoli, Claudia
author_sort del Bosque-Plata, Laura
collection PubMed
description TCF7L2 is the most potent locus for type 2 diabetes (T2D) risk and the first locus to have been robustly reported by genomic linkage studies. TCF7L2 is a transcription factor that forms a basic part of the Wnt signaling pathway. This gene has highly conserved sequence regions that correspond to functional domains. The association of TCF7L2 with T2D is one of the most powerful genetically discovered in studies of complex diseases, as it has been consistently replicated in multiple populations with diverse genetic origins. The mechanisms over which TCF7L2 exerts its effect on T2D are still not well understood. In this article, we describe the main molecular mechanisms of how TCF7L2 is related to T2D. TCF7L2 variants associated with T2D risk exert an influence on the initial therapeutic success of the hypoglycemic oral agent sulfonylurea. Thus, it is important to know whether there are other TCF7L2 variants associated with T2D that can influence treatment with oral hypoglycemic agents. Resequencing of the TCF7L2 gene in diverse ethnic groups is required to reveal common and rare variations and their role in different pathologies and in adverse reactions to drugs. Identification of TCF7L2-susceptibility disease variants will permit, at a given moment, offering of therapies to patients according to their genotype.
format Online
Article
Text
id pubmed-8275893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-82758932022-03-17 The Role of TCF7L2 in Type 2 Diabetes del Bosque-Plata, Laura Martínez-Martínez, Eduardo Espinoza-Camacho, Miguel Ángel Gragnoli, Claudia Diabetes Perspectives in Diabetes TCF7L2 is the most potent locus for type 2 diabetes (T2D) risk and the first locus to have been robustly reported by genomic linkage studies. TCF7L2 is a transcription factor that forms a basic part of the Wnt signaling pathway. This gene has highly conserved sequence regions that correspond to functional domains. The association of TCF7L2 with T2D is one of the most powerful genetically discovered in studies of complex diseases, as it has been consistently replicated in multiple populations with diverse genetic origins. The mechanisms over which TCF7L2 exerts its effect on T2D are still not well understood. In this article, we describe the main molecular mechanisms of how TCF7L2 is related to T2D. TCF7L2 variants associated with T2D risk exert an influence on the initial therapeutic success of the hypoglycemic oral agent sulfonylurea. Thus, it is important to know whether there are other TCF7L2 variants associated with T2D that can influence treatment with oral hypoglycemic agents. Resequencing of the TCF7L2 gene in diverse ethnic groups is required to reveal common and rare variations and their role in different pathologies and in adverse reactions to drugs. Identification of TCF7L2-susceptibility disease variants will permit, at a given moment, offering of therapies to patients according to their genotype. American Diabetes Association 2021-06 2021-07-02 /pmc/articles/PMC8275893/ /pubmed/34016596 http://dx.doi.org/10.2337/db20-0573 Text en © 2021 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
spellingShingle Perspectives in Diabetes
del Bosque-Plata, Laura
Martínez-Martínez, Eduardo
Espinoza-Camacho, Miguel Ángel
Gragnoli, Claudia
The Role of TCF7L2 in Type 2 Diabetes
title The Role of TCF7L2 in Type 2 Diabetes
title_full The Role of TCF7L2 in Type 2 Diabetes
title_fullStr The Role of TCF7L2 in Type 2 Diabetes
title_full_unstemmed The Role of TCF7L2 in Type 2 Diabetes
title_short The Role of TCF7L2 in Type 2 Diabetes
title_sort role of tcf7l2 in type 2 diabetes
topic Perspectives in Diabetes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275893/
https://www.ncbi.nlm.nih.gov/pubmed/34016596
http://dx.doi.org/10.2337/db20-0573
work_keys_str_mv AT delbosqueplatalaura theroleoftcf7l2intype2diabetes
AT martinezmartinezeduardo theroleoftcf7l2intype2diabetes
AT espinozacamachomiguelangel theroleoftcf7l2intype2diabetes
AT gragnoliclaudia theroleoftcf7l2intype2diabetes
AT delbosqueplatalaura roleoftcf7l2intype2diabetes
AT martinezmartinezeduardo roleoftcf7l2intype2diabetes
AT espinozacamachomiguelangel roleoftcf7l2intype2diabetes
AT gragnoliclaudia roleoftcf7l2intype2diabetes